TY  - JOUR
AU  - Barcenas, C H
AU  - Hurvitz, S A
AU  - Di Palma, J A
AU  - Bose, R
AU  - Chien, A J
AU  - Iannotti, N
AU  - Marx, G
AU  - Brufsky, A
AU  - Litvak, A
AU  - Ibrahim, E
AU  - Alvarez, R H
AU  - Ruiz-Borrego, M
AU  - Chan, N
AU  - Manalo, Y
AU  - Kellum, A
AU  - Trudeau, M
AU  - Thirlwell, M
AU  - Garcia Saenz, J
AU  - Hunt, D
AU  - Bryce, R
AU  - McCulloch, L
AU  - Rugo, H S
AU  - Tripathy, D
AU  - Chan, A
AU  - CONTROL Study Investigators
PY  - 2020
DO  - 10.1016/j.annonc.2020.05.012
UR  - http://hdl.handle.net/10668/15648
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxis was mandated,...
LA  - en
KW  - HER2-positive breast cancer
KW  - diarrhea prophylaxis
KW  - neratinib
KW  - quality of life
KW  - tyrosine kinase inhibitor
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Humans
KW  - Quality of Life
KW  - Quinolines
KW  - Receptor, ErbB-2
KW  - Trastuzumab
TI  - Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
TY  - research article
VL  - 31
ER  -